Table 1

(A) Rate of services per patient 6 months before and after the switch, the difference and p values (paired t-test); (B) number of patients with no registered use of services; and (C) number of patients with changes in number of services

A. Mean rate of services per patientC. Patients with changes in number of services, n (% of patients who change)
ServiceBeforeAfterDifferenceP levelB. Non-users (% of all)LessUnchangedMore
Outpatient visit1.441.450.000.91427 (56)107 (31)139 (41)96 (28)
Nurse activity0.610.58–0.030.22601 (78)53 (32)69 (41)46 (27)
csDMARD0.300.320.020.36595 (77)73 (42)27 (16)74 (43)
Intravenous needle0.360.370.010.61666 (87)28 (27)38 (37)37 (36)
Infliximab treatment3.102.96–0.13<0.0111 (1)229 (30)330 (44)199 (26)
Consultation regarding treatment0.090.07–0.020.12723 (94)24 (52)5 (11)17 (37)
Phone consultation1.031.170.140.03237 (31)219 (41)65 (12)248 (47)
Patient guidance0.350.490.14<0.01584 (76)47 (25)48 (26)90 (49)
Intravenous medication0.030.110.08<0.01697 (91)16 (22)2 (3)54 (75)
Methotrexate0.600.610.010.73557 (72)84 (40)48 (23)80 (38)
US shoulder, elbow, hand0.090.07–0.020.23689 (90)42 (53)7 (9)31 (39)
US hip, knee, foot0.080.100.010.30681 (90)35 (40)410 (11)43 (49)
Clinical investigation0.310.470.16<0.01552 (72)53 (24)63 (29)101 (47)
Clinical control2.082.260.19<0.01206 (27)153 (27)198 (35)212 (38)
Observation0.170.220.05<0.01714 (93)7 (13)22 (40)26 (47)
BP measurement0.610.60–0.010.70611 (79)39 (25)75 (47)44 (28)
  • BP, blood pressure; csDMARD, conventional synthetic disease-modifying antirheumatic drug; US, ultrasound.